Search Result

Isoforms Recommended:	MMP-13

Results for "

MMP13

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MMP (76) Akt (1) Angiotensin Receptor (3) AP-1 (3) Apoptosis (7) ASK1 (2) Autophagy (3) COX (2) Endogenous Metabolite (1) ERK (1) Exosomes (1) Fluorescent Dye (3) Isotope-Labeled Compounds (1) JNK (2) NF-κB (4) P2Y Receptor (1) p38 MAPK (5) PGE synthase (1) Potassium Channel (1) Ras (1) Reference Standards (8) Ser/Thr Protease (1) Small Interfering RNA (siRNA) (3) SOD (2) TGF-beta/Smad (4) TGF-β Receptor (5) TNF Receptor (4) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (31) Cardiovascular Disease (18) Endocrinology (2) Inflammation/Immunology (39) Metabolic Disease (2) Neurological Disease (9)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: MMP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12270

T-5224 Maximum Cited Publications 100 Publications Verification	AP-1 MMP	Neurological Disease Inflammation/Immunology Cancer
T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .

HY-P99590

Sotatercept 2 Publications Verification ACE-011; MK-7962	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-N1463

Luteolin 7-O-glucuronide 3 Publications Verification Luteolin 7-glucuronide	MMP	Neurological Disease Inflammation/Immunology
Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases *(MMP)* activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-110397

KP-457 3 Publications Verification	MMP	Cardiovascular Disease
KP-457 is a selective a disintegrin and metalloproteinase 17 (ADAM17) inhibitor, with higher selectivity for ADAM17 than for other MMPs and ADAM10, and IC₅₀s are 11.1 nM (ADAM17), 748 nM (ADAM10), 717 nM (MMP2), 9760 nM (MMP3), 2200 nM (MMP8), 5410 nM (MMP9), 930 nM (MMP13), 2140 nM (MMP14), and 7100 nM (MMP17), respectively.

HY-100113

Buloxibutid 5 Publications Verification AT2 receptor agonist C21	Angiotensin Receptor p38 MAPK TGF-beta/Smad TGF-β Receptor MMP	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Buloxibutid (AT2 receptor agonist C21) is an orally active, selective angiotensin II type 2 receptor (AT2R) agonist, with a K_i value of 0.4 nM for porcine AT2R. Buloxibutid exerts effects such as vasodilation, anti-inflammation, anti-fibrosis (promoting the expression of collagenase *MMP-13) and tissue repair mainly by activating the NO/cGMP* pathway, inhibiting the pro-proliferative MAPK signaling, and suppressing the pro-fibrotic TGF-β/Smad pathway as well as the inflammatory NF-κB pathway. Buloxibutid can be used in research related to idiopathic pulmonary fibrosis, hypertension, and systemic sclerosis .

HY-N1454

Apigenin-7-glucuronide 4 Publications Verification Apigenin 7-O-glucuronide	MMP	Cancer
Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases *(MMP)* activities, with IC₅₀s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-107394

UK 356618 5+ Cited Publications	MMP	Inflammation/Immunology Cancer
UK 356618 (Compound 4j) is a potent and selective inhibitor of matrix metalloprotease-3 (MMP-3) with an IC₅₀ of 5.9 nM. UK 356618 is less potent against MMP-1, MMP-2, MMP-9, MMP-13 and MMP-14 compared with *MMP-3* .

HY-P4931

Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 1 Publications Verification Mca-Lys-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2	MMP	Cancer
Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 (FS-6) is a fluorescent peptide that is a quenched MMP peptide substrate. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 can be used for real-time quantification of MMP enzymatic activity. Mca-Lys-Pro-Leu-Gly-Leu-Dap(Dnp)-Ala-Arg-NH2 is an elongated peptide of MMP substrate (FS-1) and is active against collagenases (MMP-1, MMP-8, MMP-13 ) and MT1-MMP with higher specificity constants than FS-1 . (Ex/Em=325 nm/400 nm)

HY-100359

CL-82198 5+ Cited Publications	MMP	Inflammation/Immunology Cancer
CL-82198 is a selective inhibitor of *MMP-13. CL-82198 binds to the entire S1’ pocket of MMP-13, which is the basis for its selectivity towards MMP-13* and the lack of inhibitory activities against other MMPs . CL-82198 is a pharmacologic treatment for preventing osteoarthritis (OA) progression .

HY-12875

BQU57	Ras	Cancer
BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and *MMP-13, and inhibits apoptosis* by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .

HY-124029

BI-4394 MMP13-IN-3	MMP	Inflammation/Immunology
BI-4394 (MMP13-IN-3), a chemical probe, is a potent, selective, and orally active *MMP-13* inhibitor (IC₅₀=1 nM ) for the potential treatment of osteoarthritis . BI-4394 is >1000 selective over other MMPs .

HY-12170

Prinomastat 4 Publications Verification AG3340; KB-R9896	MMP Apoptosis	Cancer
Prinomastat (AG3340) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC₅₀s of 79, 6.3 and 5.0 nM for *MMP-1, MMP-3* and *MMP-9, respectively. Prinomastat inhibits MMP-2, MMP-3, MMP-13* and *MMP-9* with K_is of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat crosses blood-brain barrier. Antitumor avtivity .

HY-100518

T-26c 3 Publications Verification	MMP	Inflammation/Immunology
T-26c, a chemical probe, is highly potent and selective matrix metalloproteinase-13 (MMP-13) inhibitor with an IC₅₀ of 6.75 pM and more than 2600-fold selectivity over the other related metalloenzymes .

HY-N2350

Cynaropicrin	MMP NF-κB TNF Receptor	Cancer
Cynaropicrin is a sesquiterpene lactone which can inhibit tumor necrosis factor (TNF-α) release with IC₅₀s of 8.24 and 3.18 μM for murine and human macrophage cells, respectively. Cynaropicrin also inhibits the increase of cartilage degradation factor (MMP13) and suppresses NF-κB signaling.

HY-108672

NF157	P2Y Receptor	Inflammation/Immunology
NF157 is a highly selective nanomolar P2Y11 antagonist with a pK_i of 7.35. The IC₅₀s are 463 nM, 1811 µM, 170 µM for P2Y11 (K_i=44.3 nM), P2Y1 (K_i=187 µM), P2Y2 (K_i=28.9 µM), respectively . NF157, significantly reduces expression of metalloproteinase (MMP)-3, MMP-13, can be used in the treatment of osteoarthritis (OA) .

HY-19820A

NSC45586 sodium 1 Publications Verification	Akt Ser/Thr Protease Apoptosis MMP	Cardiovascular Disease Neurological Disease Inflammation/Immunology
NSC45586 sodium is an inhibitor of PHLPP. NSC45586 sodium targets the PP2C phosphatase domains of PHLPP1 and PHLPP2, blocks the phosphatase activity of PHLPP, increases the expression level of FOXO1 in the nucleus, and reduces the protein expression of PHLPP1. NSC45586 sodium activates the AKT survival signaling pathway, enhances IGF-1-induced AKT activation, and inhibits the phosphorylation of AKT/ERK under basal conditions. NSC45586 sodium reduces staurosporine-induced neuronal death, preserves notochord cell morphology and KRT19 expression, inhibits cell apoptosis (apoptosis), improves the viability and proliferation of nucleus pulposus cells, upregulates the expression of ACAN/SOX9, and downregulates the expression of *MMP13. NSC45586 sodium binds tightly to bovine serum albumin (bovine serum albumin*), and exerts a more significant effect on nucleus pulposus in male individuals. NSC45586 sodium can be used in studies related to global cerebral ischemia and intervertebral disc degeneration .

HY-122624

MMP13-IN-2	MMP	Inflammation/Immunology
MMP13-IN-2 is a potent, selective and orally active *MMP-13* inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC₅₀=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .

HY-125166

DB04760 1 Publications Verification	MMP	Neurological Disease Cancer
DB04760 (compound 4) is a potent, highly selective, non-zinc-chelating *MMP-13* inhibitor with an IC₅₀ of 8 nM . DB04760 significantly reduces paclitaxel neurotoxicity and has anticancer activity .

HY-19485

XL-784 2 Publications Verification	MMP	Cardiovascular Disease
XL-784 is a selective matrix metalloproteinases (MMP) inhibitor, with IC₅₀s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-10398

CTS-1027 4 Publications Verification Ro 1130830; RS 130830	MMP	Cancer
CTS-1027 is a potent small molecule inhibitor of *MMPs, with IC₅₀s of 0.3 nM, 0.5 nM for MMP2, MMP13, respectively, and has > 1,000 fold selectivity over MMP1*.

HY-12170A

Prinomastat hydrochloride 4 Publications Verification AG3340 hydrochloride; KB-R9896 hydrochloride	MMP Apoptosis	Cancer
Prinomastat hydrochloride (AG3340 hydrochloride) is a broad spectrum, potent, orally active metalloproteinase (MMP) inhibitor with IC₅₀s of 79, 6.3 and 5.0 nM for *MMP-1, MMP-3* and *MMP-9, respectively. Prinomastat hydrochloride inhibits MMP-2, MMP-3, MMP-13* and *MMP-9* with K_is of 0.05 nM, 0.3 nM, 0.03 nM and 0.26 nM, respectively. Prinomastat hydrochloride can cross blood-brain barrier. Antitumor avtivity .

HY-12093

MMP408 1 Publications Verification	MMP	Inflammation/Immunology
MMP408 is a selective and orally effective inhibitor of *MMP-12* with IC₅₀ values for human, mouse and rat *MMP-12* of 2 nM, 160 nM and 3 μM respectively. MMP408 exhibits IC₅₀ value for human *MMP-13* of 120 nM, and its activity against other MMPs is weak. MMP408 can alleviate inflammation, fibrosis and tissue remodeling by inhibiting MMP-12. MMP408 can be used in the research of chronic obstructive pulmonary disease and chronic sinusitis with nasal polyps .

HY-128026

MMP-9/MMP-13 Inhibitor I	MMP	Inflammation/Immunology
MMP-9/MMP-13 Inhibitor I is a potent *MMP-9* and *MMP-13* inhibitor with IC₅₀s of both 0.9 nM. MMP-9/MMP-13 Inhibitor I shows >20-folds selectivity for MMP-9/MMP-13 over other MMPs .

HY-107428

PD-166793	MMP	Cardiovascular Disease
PD-166793 is a potent, selective, orally active and wide-broad spectrum inhibitor of *MMP, exhibiting nanomolar potency against MMP-2, MMP-3* and *MMP-13* (IC₅₀=4, 7, and 8 nM, respectively) and micromolar potency vs *MMP-1, -7 and -9 (IC₅₀*=6.0, 7.2, and 7.9 μM, respectively). PD-166793 can attenuate left ventricular remodeling and dysfunction in a rat model of progressive heart failure .

HY-107639

UK-370106	MMP	Inflammation/Immunology
UK-370106 is a potent and highly selective *MMP-3* (IC₅₀ of 23 nM) and *MMP-12* (IC₅₀ of 42 nM) inhibitor with >1200-fold higher potency than MMP-1, MMP-2, MMP-9, and MMP-14, and about 100-fold than MMP-13 and MMP-8. UK-370106 potently inhibits cleavage of [ ³H]-fibronectin by *MMP-3* (IC₅₀ of 320 nM) and has little effect on keratinocyte migration in vitro .

HY-12168

Tanomastat BAY 12-9566	MMP	Cancer
Tanomastat (BAY 12-9566) is an orally bioavailable, non-peptidic biphenyl matrix metalloproteinases (MMPs) inhibitor with a Zn-binding carboxyl group. The K_i values are 11, 143, 301, and 1470 nM for MMP-2, MMP-3, MMP-9, MMP-13 respectively. Tanomastat shows anti-invasive and antimetastatic activity in several experimental tumor models .

HY-P2414

MMP-13 Substrate	MMP	Inflammation/Immunology
MMP-13 Substrate is a substrate of MMP-13. MMP-13 Substrate can be used for the research of osteoarthritis (OA) .

HY-N1508

Ecliptasaponin A	MMP Apoptosis Autophagy NF-κB TNF Receptor COX Toll-like Receptor (TLR) SOD ASK1 JNK	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and *MMP-9. Ecliptasaponin A can enhance SOD* activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of *MMP13* and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors .

HY-W011085

CP-471474 1 Publications Verification	MMP	Inflammation/Immunology
CP-471474 is an orally active and pan *MMP* inhibitor, with IC₅₀ values of 1170 nM (MMP-1), 0.7 nM (MMP-2), 16 nM (MMP-3), 13 nM (MMP-9) and 0.9 nM (MMP-13), respectively .

HY-116302

MMP-9-IN-9	MMP	Neurological Disease Inflammation/Immunology
MMP-9-IN-9 (compound 4f) is a slective *MMP-9* inhibitor with an IC₅₀ of 5 nM. MMP-9-IN-9 shows selective for MMP-9 over MMP-1 and MMP-13. MMP-9-IN-9 shows strong anti-inflammatory and neuroprotective effects .

HY-147745

MMP2-IN-2	MMP	Cancer
MMP2-IN-2 (compound 42) is a potent and selective *MMP-2* (matrix metalloproteinases) inhibitor, with an IC₅₀ of 4.2 μM. MMP2-IN-2 also shows inhibitory activity against *MMP-13, MMP-9* and *MMP-8, with IC₅₀* values of 12, 23.3, and 25 μM, respectively .

HY-117970

MMPI-1154	MMP	Cardiovascular Disease
MMPI-1154 is a promising novel cardio-cytoprotective imidazole-carboxylic acid (ICA) *MMP-2* inhibitor(IC₅₀=6.6 μM) and can be used for the study of acute myocardial infarction. MMPI-1154 also inhibits the activity of MMP-13, MMP-1 and MMP-9 with IC₅₀s of 1.8 μM,10 μM, and 13 μM, respectively .

HY-N2503

Ginsenoside F4	Apoptosis MMP	Inflammation/Immunology
Ginsenoside F4 (GF4), ginseng saponinis, isolated from notoginseng or red ginseng. Ginsenoside F4 (GF4) has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis . Ginsenoside F4 (GF4) inhibits matrix metalloproteinase 13 (MMP 13) expression in IL-1β-treated chondrocytes and blocks cartilage breakdown in rabbit cartilage tissue culture, shows therapeutic potential for preventing cartilage collagen matrix breakdown in diseased tissues .

HY-114091

PF-00356231 hydrochloride 2 Publications Verification	MMP	Inflammation/Immunology
PF-00356231 hydrochloride is a specific, non-peptidic, non-zinc chelating ligand and inhibitor of matrix metalloproteinase *MMP-12* (IC₅₀=1.4 μM). PF-00356231 hydrochloride binds to MMP-12 and forms PF-00356231/MMP-12 complex. PF-00356231 hydrochloride shows potency against MMP-13, MMP-8, MMP-9, MMP-3 with IC₅₀s of 0.00065, 1.7, 0.98, 0.39 μM, respectively .

HY-RS08526

Mmp13 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) MMP	Others
Mmp13 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mmp13 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mmp13 Mouse Pre-designed siRNA Set A Mmp13 Mouse Pre-designed siRNA Set A

HY-RS08525

MMP13 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) MMP	Others
MMP13 Human Pre-designed siRNA Set A contains three designed siRNAs for MMP13 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

MMP13 Human Pre-designed siRNA Set A MMP13 Human Pre-designed siRNA Set A

HY-P2414A

MMP-13 Substrate TFA	MMP	Inflammation/Immunology
MMP-13 Substrate TFA is a substrate of MMP-13. MMP-13 Substrate TFA can be used for the research of osteoarthritis (OA) .

HY-RS08527

Mmp13 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) MMP	Others
Mmp13 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mmp13 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Mmp13 Rat Pre-designed siRNA Set A Mmp13 Rat Pre-designed siRNA Set A

HY-120505

ITZ-1	ERK p38 MAPK	Inflammation/Immunology
ITZ-1 is an orally active and selective extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway inhibitor with an IC₅₀ of 0.51 μM for inhibiting interleukin-1β (IL-1β)-induced matrix metalloproteinase-13 (MMP-13) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO)-induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases .

HY-112160

XL-784 free base	MMP	Cardiovascular Disease
XL-784 free base is a selective matrix metalloproteinases (MMP) inhibitor, with IC₅₀s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13, respectively .

HY-P3699

TNO003	MMP Fluorescent Dye	Others
TNO003 is a selective fluorogenic substrate for stromelysin-1 (MMP-3). TNO003 has higher selectivity for MMP-3 than MMP-1, MMP-2, MMP-7, MMP-8, MMP-9 and MMP-13. TNO003 can be used for the determination of stromelysin activity (Ex/Em = 360/490 nm) .

HY-N1454R

Apigenin-7-glucuronide (Standard) Apigenin 7-O-glucuronide (Standard)	Reference Standards MMP	Cancer
Apigenin-7-glucuronide (Standard) is the analytical standard of Apigenin-7-glucuronide. This product is intended for research and analytical applications. Apigenin-7-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 12.87, 22.39, 17.52, 0.27 μM for MMP-3, MMP-8, MMP-9, MMP-13, respectively.

HY-149377

MMP13-IN-4	MMP	Metabolic Disease
MMP13-IN-4 (compound 13) is a potent and selective inhibitor of *MMP-13* (IC₅₀=14.6 μM)，involved in osteoarthritis (OA) .

HY-154868

MMP-13-IN-1	MMP	Cardiovascular Disease Cancer
MMP-13-IN-1 is a potent and selective inhibitor of *MMP-13* with a IC₅₀ value of 16 nM. MMP-13-in-1 can be used for atherosclerosis research .

HY-14237

SC-77964	MMP	Inflammation/Immunology Cancer
SC-77964 is a potent, selective and orally active matrix metalloprotease (MMP) inhibitor. SC-77964 shows IC₅₀ values < 0.1 nM against MMP-2, MMP-9, and MMP-13. SC-77964 can be used for the research of cancer and inflammation, such as melanoma .

HY-107640

WAY-170523	MMP	Cancer
WAY-170523 is a potent and selective MMP-13 (matrix metalloproteinase-13) inhibitor, with an IC₅₀ of 17 nM. WAY-170523 can directly attenuate ERK1/2 phosphorylation. WAY-170523 inhibits the invasion of PC-3 cells, can be used for prostate cancer research .

HY-149378

MMP13-IN-5	MMP	Metabolic Disease
MMP13-IN-5 (compound 13m) is a potent and selective inhibitor of *MMP-2/MMP-13* (IC₅₀=3.6 μM/14.6 μM)，involved in osteoarthritis (OA) .

HY-N2199

Sotetsuflavone	Apoptosis Autophagy	Cancer
Sotetsuflavone is a flavonoid that can be isolated from Cycas revolute. Sotetsuflavone inhibits migration and invasion of A549 cells by reversing EMT, and induces cell apoptosis and autophagy. Sotetsuflavone inhibits HIF-1α, VEGF, angiostatin, MMP-9, and MMP-13 expression in A549 cells. Sotetsuflavone also protects mice against Crohn's disease (CD)-like colitis. Sotetsuflavone can be used for research of NSCLC .

HY-N1463R

Luteolin 7-O-glucuronide (Standard) Luteolin 7-glucuronide (Standard)	Reference Standards MMP	Neurological Disease Inflammation/Immunology
Luteolin 7-O-glucuronide (Standard) is the analytical standard of Luteolin 7-O-glucuronide. This product is intended for research and analytical applications. Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC₅₀s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively .

HY-12270R

T-5224 (Standard)	AP-1 MMP	Others
T-5224 (Standard) is the analytical standard of T-5224. This product is intended for research and analytical applications. T-5224 is a transcription factor c-Fos/activator protein (AP)-1 inhibitor with anti-inflammatory effects, which specifically inhibits the DNA binding activity of c-Fos/c-Jun without affecting other transcription factors. T-5224 inhibits the IL-1β-induced up-regulation of Mmp-3, Mmp-13 and Adamts-5 transcription .

Cat. No.	Product Name	Category	Target	Chemical Structure